AI assistant
RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2021
Mar 16, 2021
30849_dirs_2021-03-16_72df09df-f0cc-4147-aaf5-1ff2e29e2968.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2021-03-15
Reporting Person: Foley Todd (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-15 | Common Stock | S | 1000000 | $25.10 | Disposed | 909258 | Indirect |
Footnotes
F1: The shares were sold as follows: 962,604 by MPM BioVentures V, L.P. ("BV V") and 37,396 by MPM Asset Management Investors BV5 LLC ("AM BV5"). MPM BioVentures V GP LLC and MPM BioVentures V LLC ("BV LLC") are the direct and indirect general partners of BV V and BV LLC is the manager of AM BV5. The Reporting Person is a member of BV LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F2: Shares are held as follows: 875,256 by BV V and 34,002 by AM BV5. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.